VIR Vir Biotechnology, Inc.

Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.

$31.30  -1.01 (-3.13%)
As of 01/27/2022 15:59:56 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/16/2013
Outstanding shares:  130,880,159
Average volume:  1,559,418
Market cap:   $4,104,401,786
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BK4PZ38
Valuation   (See tab for details)
PE ratio:   -41.33
PB ratio:   4.82
PS ratio:   14.52
Return on equity:   0.38%
Net income %:   1.18%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy